Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Neos Therapeutics, Inc. | neos-20191231ex3211eac6d.htm |
| EX-31.2 - EX-31.2 - Neos Therapeutics, Inc. | neos-20191231ex312c147a7.htm |
| EX-31.1 - EX-31.1 - Neos Therapeutics, Inc. | neos-20191231ex311e309b6.htm |
| EX-21.1 - EX-21.1 - Neos Therapeutics, Inc. | neos-20191231ex21185da5c.htm |
| EX-10.29 - EX-10.29 - Neos Therapeutics, Inc. | neos-20191231ex1029157c2.htm |
| EX-10.27 - EX-10.27 - Neos Therapeutics, Inc. | neos-20191231ex1027873fa.htm |
| EX-10.25 - EX-10.25 - Neos Therapeutics, Inc. | neos-20191231ex10251174c.htm |
| EX-4.3 - EX-4.3 - Neos Therapeutics, Inc. | neos-20191231ex43783dff0.htm |
| 10-K - 10-K - Neos Therapeutics, Inc. | neos-20191231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S‑3 (No. 333-230357, No. 333‑228748, No. 333‑219108 and No. 333‑212809) and Form S‑8 (No. 333-230356, No. 333‑226044, No. 333‑223696, No. 333‑216698, No. 333‑210267 and No. 333‑205937) of Neos Therapeutics, Inc. of our report dated March 13, 2020, relating to the consolidated financial statements and the financial statement schedule of Neos Therapeutics, Inc. appearing in this Annual Report on Form 10‑K of Neos Therapeutics, Inc. for the year ended December 31, 2019.
/s/ RSM US LLP
Dallas, Texas
March 13, 2020